Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aritra Gangopadhyay

INSANE: Gilead sciences stock analyst estimates ratings dwvfczed | Vintage Vibes

Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States and internationally. The company has a market cap of $211.2 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.

GILD stock has rallied the broader market over the past year, surging 42.2% compared to the S&P 500 Index’s ($SPX) 10.3% surge. Moreover, in 2026, the stock has risen by nearly 38.8%, outperforming the SPX’s 10.2% rise.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.